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1. Introduction 
Throughout human evolution, plants have provided us with food, fibers to produce clothes, 
and medicines to treat different kind of diseases. In fact, we could say that plants represent 
the “chemists” of the antiquity. Examples of important therapeutic molecules obtained from 
plants are morphine, atropine, ephedrine, codeine, and digitalin and so on (Farnsworth et 
al., 1985). Plants have always been a common source of medicaments, either in the form of 
traditional preparations or as pure active principles. For many people worldwide, natural 
plant-based remedies are used to treat both acute and chronic health problems. Indeed, 
about 40% of the drugs prescribed in the USA and Europe come from active compounds 
found in plants (Rates, 2001; Sivakumar, 2006). The chemical synthesis of these plant-
derived compounds led to the production of pharmaceuticals at an industrial level, allowing 
the development of medicament industry. These active compounds from plants have been 
basically small molecules. Aspirin, one of the most famous medicaments, was developed as 
an analogous of the salicylic acid extracted from willow bark in the 19st century (Knäblein, 
2005). Moreover, the development of more sophisticated extraction and purification 
procedures allowed the extraction of alkaloids (morphine) and other kind of molecules from 
plants and mammals (Liénard et al., 2007). However, chemical synthesis has some 
limitations to produce complex therapeutic molecules such as antibodies. So, many 
therapeutic molecules have to be isolated and purified from living material (e.g. from blood 
plasma), which involves a high risk of transmission of pathogens to the manufactured 
product (Engelhard, 2007). 
The emergence of genetic engineering in the early 1970s has made possible a new way to 
produce pharmaceuticals outside their natural host. The term “biopharmaceutical” appears 
to be originated in the 1980s and is used to refer to therapeutic proteins produced by 
modern biotechnological techniques (Walsh, 2005a). Genetic transformation techniques have 
allowed the scientist to transform living organisms like bacteria, yeast, animal cells and 
plants into production “biofactories”. These organisms are forced to produce customized 
therapeutics making possible the treatment of diseases like genetic disorders, AIDS, and 
diabetes. Unlike chemically produced therapeutics, biopharmaceuticals are our own 
molecules and hence more compatible with biological systems (Rai & Padh, 2001).  
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Biopharmaceuticals represent the fastest growing sector within pharmaceutical industry, 
with worldwide sales of $94 billion from the total market of $600 billion in 2007. In 2009, 
biopharmaceuticals recorded global sales of $99 billion ($61 billion for therapeutic proteins 
and $38 billion for monoclonal antibody (mAb)-based products (Walsh, 2010), and these 
numbers are expected to reach sales of $125 billion by the year 2015 (Xu et al., 2011). 
Regarding the most lucrative molecules, mAb-based products indicated for treating cancer 
are the bestsellers of biopharmaceuticals. The next most lucrative group is represented by 
insulin and insulin analogs, generating $13.3 billion in sales, followed by EPO-based 
products whose sales stands at $9.5 billion (Walsh, 2010). 
The biopharmaceutical industry relies basically in non-human mammalian cell lines like 
CHO cells, and bacterial systems. In mammalian cell lines human proteins are correctly 
processed and modified, but the scalability is limited, maintenance of bioreactors is 
expensive, and there is a risk of contamination of the product with human pathogens 
(Daniell et al., 2001; Twyman et al., 2005). Escherichia coli was the pioneer expression system 
and in 1977 it was used for the successful expression of somatostatin (growth hormone-
inhibiting hormone). E. coli is widely used because it is the most cost-effective production 
system, allowing the large-scale production of proteins (Rai & Padh, 2001). Insulin produced 
in E. coli, also known as “humulin”, received the marketing authorization in 1982 which 
represented the beginning of the biopharmaceutical industry (Walsh, 2005b). However, the 
prokaryotic nature of this organism limits the complexity of the proteins that can be 
correctly processed, and the appearance of inclusion bodies increases the cost of the product 
(Boehm, 2007). Yeast-based systems are able to grow in well-defined simple media, in large-
scale bioreactors and at high cell-densities (Gerngross, 2004). Therefore interferon was 
expressed in yeast (1981). However, the low product yields, inefficient protein secretion and 
hyperglycosylation of proteins (addition of large number of mannose residues) are common 
in problems in this system. Transgenic animals allow the scaling-up of protein production 
but they require long generation times, and have technical difficulties. Moreover, ethical 
aspects also limit this system (Hunter et al., 2005). Insect cell-based systems provide a 
eukaryotic expression system readily amenable to scale-up, but they are inefficient in 
proteolytic cleavage of proteins as well as for glycosylation (Rai & Padh, 2001). 
Nevertheless, ┚ interferon and factor IX were expressed in insect cells (1983) and transgenic 
animals (1988), respectively (Desai et al., 2010). 
Genetic engineering techniques have made it possible to produce therapeutic molecules 
using different host system. But what are the ideal characteristics that should satisfy an 
expression system to be considered a good system? It is important to (1) produce proteins 
with the correct conformation and biologically active, (2) allow good productivities, (3) have 
minor economic costs associated to manufacturing and purification, and (4) be recognized as 
safe system by the society.  
Despite the variety of expression systems available for biopharmaceutical industry, none of 
them meets completely all the requirements for a production system to be able to produce 
any kind of therapeutic protein. There is no ideal or universal expression system. All of 
them have some advantages and some limitations, so the choice for the best system should 
be done by evaluating biological as well as economic aspects, and bearing in mind the 
purpose of the product of interest. 
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2. Transgenic plants as production platform for biopharmaceuticals 
The total global market for biopharmaceuticals is projected to grow at between 7% and 15% 
annually over the next several years, with mAb-based approvals continuing to dominate 
(Walsh, 2010). Efforts on human genome project have identified new proteins with 
therapeutic potential and the growing number of candidates in clinical trials will be in the 
market in the next years. So it just keeps getting more apparent that the traditional systems 
used by the industry so far will not be able to meet the growing demand and will represent 
a bottleneck in bringing therapeutic proteins to the society. Pharmaceutical industry 
requires a production platform able to provide enough quantity of safe and high-quality 
products at the lowest cost. Transgenic plants are becoming one of the most interesting 
alternative systems for biopharmaceutical production as they offer many advantages over 
traditional systems.  
One of the most important benefits of transgenic plants is the capacity to obtain high 
production volumes at relatively low cost, due to their flexibility in terms of scale-up 
(Sparrow et al., 2007). It has been estimated that the cost associated with the production of 
300 kg of a secretory antibody in maize or tobacco plants is 0.5-2 million $ per year, while 
the cost increases to 6-7 million per year using transgenic goat or mammalian cell cultures 
(Gerlach et al., 2010). Transgenic plants allow the increase or decrease of cultivated area 
depending on the market demand. Moreover, the availability of harvesting, storage and 
transport infrastructures turns plants into a very efficient production system (Kusnadi et al., 
1997). 
As eukaryotic organisms, protein synthesis pathways are highly conserved among plants 
and animals, so plant cells are able to correctly fold and assemble proteins as well as to 
perform post-translational modifications required for protein activity and stability 
(Kamenarova et al., 2005). This is demonstrated by the ability of plant cells to produce 
various types of antibodies, such as IgGs and IgAs, which are complex proteins requiring 
the assembly of various polypeptide chains through disulphide bonds (Twyman et al., 
2003). Apart from cultured mammalian cells, only plants are able to assembly the light and 
heavy chains of antibodies (Gomord et al., 2004). For this reason, amino acid sequences of 
human proteins expressed in plant cells are usually the same as native counterparts, which 
ensures the quality of products produced in plants (Schillberg & Twyman, 2007). Moreover, 
plant cells have a very high ratio of biologically active protein (92% of total protein in 
tobacco BY-2 cells) when compared to E. coli (12%) and P. pastoris (40%) (Boehm, 2007). 
Proteins produced in plant cells are less likely to be contaminated with human or animal 
pathogens and hence product safety can be guaranteed.  
The diversity of plant host makes possible the production of oral vaccines in edible parts of 
the plant, eliminating the need of cold-chain and economic costs associated with purification 
processes, and thus being more amenable for developing countries. Moreover, tissues like 
seeds, tubers or fruits allow the storage and stability of biopharmaceuticals produced in 
plants (Desai et al., 2010). 
One of the major challenges of plant systems, besides low protein expression level which 
will be discussed below is the inability of plants, as in other eukaryotic systems, to perfectly 
reproduce human-type glycosylation on biopharmaceuticals. Glycosylation is the most 
widespread post-translational modification with more than half of the human 
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biopharmaceuticals being glycoproteins. Glycosylation affects their function, plasma half-
life and/or biological activity (Saint-Jore-Dupas et al., 2007). Main differences between 
plants and mammal cells are relative to modification of glycans in Golgi apparatus. Plants 
do not have sialic acid residues present in human glycoproteins, and add ┙ (1,3)-fucose and 
┚ (1,2)-xylose residues which are responsible of immunogenic response in human therapy 
(Chen et al., 2005). However, there are some strategies available to “humanize” recombinant 
glycoprotein produced in plants. The first one is based on endoplasmatic reticulum (ER) 
retention of proteins in their biosynthetic pathway bypassing Golgi apparatus. This can be 
done through the addition on KDEL sequence in the recombinant protein (Gomord & Faye, 
2004). The second one relies on inactivation or down-regulation of plant xylosyltransferase 
and fucosyltransferase using RNA interference technology. Alternatively it is possible to 
“humanize” glycoproteins co-expressing human glycosyltransferases (Gomord et al., 2004) 
or by in vitro galactosylation of recombinant proteins using mammalian enzymes (Bardor et 
al., 2003). 
Another future challenge for plants is the concern about biosafety and regulatory issues. 
General public is very reluctant to transgenic crops, especially since the appearance of those 
resistant to pests or pesticides, and unfortunately transgenic plants for biopharmaceutical 
production must suffer the same rejection. The main biosafety problems are related to risks 
associated to human/animal health and to the environment, so it is very important to 
evaluate and manage carefully those risks through risk assessments (Peterson & Arntzen, 
2004). There are many strategies available to avoid those problems: apart from delimitation 
of physic barriers and strict agricultural management (crop destruction, field cleaning, and 
crop rotation) to avoid mixing of modified and food/feed crops, the most obvious 
alternative is the use of non-food/feed crops (tobacco, Arabidopsis thaliana, Phiscomitrella 
patens, Lemna sp.), or the use of greenhouses/glasshouses where crops are confined and 
controlled. Biological containment provides a natural and additional barrier to gene flow. 
Production of biopharmaceuticals in self-pollinating species (rice, wheat, and pea) or 
engineering other species to make them cleistogamic (self-pollination before flower 
opening) is interesting for gene containment (Commandeur et al., 2003). 
Biotechnological tools have allowed the development of different strategies for gene and 
protein containment. Chloroplast transformation technology is a very attractive approach as 
chloroplast genome is maternally inherited in most crops, and gene spread via pollen occurs 
at low frequency (Svab & Maliga, 2007). The use of male-sterile plants (Gils et al., 2008) or 
“terminator” technology (also known as GURTs, “Genetic use restriction technologies), 
which is based on a repressible system to produce plants with non-viable seeds unless the 
plants are exposed to specific activators (Lee & Natesan, 2006), have also been used to 
contain transgenes. Other strategies include organ- or tissue-specific expression of 
transgenes, ER-retention of proteins and inducible promoters (Obembe et al., 2010).  
It is clear that taking into account the previously reported concerns regarding health and 
environmental risks, transgenic plants producing biopharmaceuticals must be regulated 
strictly, and in fact they are. However, there is a need for the harmonization of international 
regulation of plants producing biopharmaceuticals in European Union and USA (Gerlach et 
al., 2010) and to unify the criterions. Plants as production system for biopharmaceuticals 
comply not only with the strict regulatory requirements covering other GM crops, but also 
the regulations set out by agencies that oversee the production of pharmaceuticals (Sparrow 
et al., 2007).  
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Plants represent a very versatile and plastic expression system to produce 
biopharmaceutical proteins, because they offer a great variety of strategies. Depending on 
production needs, product quality, or compliance with certain legal requirements, we can 
choose between different plant-based systems without the need to use bacteria or animal 
cells.  
The most used strategy for protein production is that based on whole plants. Most 
biopharmaceuticals are produced in nuclear transformed plants, which are obtained mainly 
by using soil pathogen Agrobacterium tumefaciens, and allow the stable expression of 
transgenes with the required post-translational modifications. Genetic transformation of 
chloroplast to obtain transplastomic plants constitutes a promising alternative strategy for 
protein production due to the important advantages over nuclear transformation. Proteins 
can achieve high expression levels due to high copy-number of transgene per cell. It has 
been reported an expression level of up to 31% of total soluble protein (TSP) for an animal 
vaccine produced in transplastomic tobacco plants (Molina et al., 2004). Chloroplast 
transformation is based on homologous recombination events so there is no gene silencing 
(Maliga, 2003). It is possible to integrate multiple genes in operons and, as previously 
mentioned, this system offers transgene containment through maternal inheritance (Bock & 
Khan, 2004). However, in the chloroplast it is not possible to carry out post-translational 
modifications present in the ER limiting the range of proteins that can be produced in this 
system. Against stable nuclear or chloroplast transformation, plants can be transiently 
transformed by agroinfiltration with A. tumefaciens, biolistic methods and viral vectors. This 
strategy is very useful for transformation construct verification and to test functionality of 
recombinant proteins (Fischer et al., 2004). 
2.1 Plant cell cultures 
As an alternative to whole plants, biopharmaceuticals can be produced using plant cell 
cultures. Plant cell culture is a very interesting and promising alternative system and has 
been used for almost two decades for protein production, as well as for secondary 
metabolite production. 
Suspended cell cultures are derived from callus, which are unorganized and generally 
undifferentiated cell aggregates derived from plant tissues cultured in solid media 
supplemented with growth regulators. Calli are suspended in liquid media to form a 
homogeneous suspension. Transgenic suspension cultures can be obtained from wild type 
callus or suspensions transformed by A. tumefaciens or biolistic methods, depending on plant 
species, but also from transgenic plant tissue such as leaf or stem. With the second approach 
there is no need for further genetic manipulation like transformed tissue selection and line 
screening (Hellwig et al., 2004). 
Since 1990, when Sijmons et al. reported the expression of human serum albumin in 
transgenic tobacco suspension cells, a diverse array of biopharmaceuticals have been 
produced using suspended cell cultures. Huang & McDonald (2009) reported an extensive 
list of recombinant proteins produced in this system, including human erythropoietin, 
human granulocyte-macrophage colony-stimulating factor (hGM-CSF), human 
interleukins, hepatitis B surface antigen, and many types of antibodies. Although 
productivity of plant cell cultures can vary considerably from 0.5 µg/L to 200 mg/L 
(Hellwig et al., 2004), many proteins have been produced at high yields (>10 mg/L) (Xu et 
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al., 2011). Most of biopharmaceutical proteins have been expressed in tobacco cells like 
well characterized BY-2 and NT-1 cell lines, because these host lines are fast-growing, well 
synchronized and susceptible to Agrobacterium mediated transformation (Nagata & 
Kumagai, 1999). Other host plants used include rice, an emerging host specie (Kim et al., 
2008), sweet potato (Min et al., 2006), tomato (Kwon et al., 2003), and carrot (Shaaltiel et 
al., 2007).  
Suspended cell cultures offer many advantages over whole plant systems, and perhaps one 
of the most important is that in vitro plant cultures, as grown in confined and sterile 
conditions, avoid the political resistance to release of genetically modified plants to the field. 
Moreover, confined culture eliminates problems related to weather conditions, soil quality, 
season, plagues, and contamination with agrochemicals and fertilizers that affect field 
grown plants (Weathers et al., 2010). This is an ideal characteristic for production of high 
purity biopharmaceuticals. Whole plant systems require longer period of time to be 
productive (sowing, growing, harvesting) while proteins could be manufactured in days or 
weeks on a time-scale compatible with that of market demands (Doran, 2000). Growth in 
bioreactors not only allows the reduction in production cycles, but also the scalability and 
the tight control of growth parameters (temperature, O2 supply, agitation, pH), ensuring 
product quality and batch-to-batch consistency, as well as product traceability (Ma et al., 
2005). These features make the system amenable to good manufacturing processes (GMP), 
facilitating compliance with regulatory and environmental requirements (Spök et al., 2008). 
Bioreactor technology provides a great variety of culture modes and bioreactor types to 
increase recombinant protein production. Large-scale culturing can be done in standard 
stirred-tank bioreactor, pneumatic bioreactor (bubble column or air-lift), wave bioreactor, 
membrane bioreactor, hollow fiber bioreactor or miniature bioreactor (Huang & McDonald, 
2009). Regarding to operation modes, we can choose between batch culture, fed-batch 
culture, continuous and semi-continuous culture, and perfusion culture (Xu et al., 2011). 
Choosing a suitable bioreactor type and operation mode should include adequate oxygen 
mass transfer to cells, low shear stress to cells, and proper nutrient supply to cells and 
product removal from cells (Huang & McDonald, 2009).  
The potential of suspended cells to secrete biologically active proteins into the culture 
medium has a big impact on downstream processing costs. Cells are grown in relative 
simple and synthetic protein free media which facilitates the recovery of proteins (Hellwig, 
2004). Protein secretion is determined by the presence of signal peptide and protein size to 
pass through wall pores. Due to their undifferentiated nature, callus cells lack functional 
plasmodesmata, and as grown in suspended form, there is minimal cell-to-cell 
communication (Su, 2006). All those features can reduce post-transcriptional gene silencing 
(PTGS) because signal transmission between cells is avoided (Doran, 2000). In conclusion, 
plant cell suspension cultures integrate many of the advantages of whole plant systems with 
those of microorganisms and mammalian cell cultures.  
In contrast to suspended cells, plant cells can also be immobilized for biopharmaceutical 
production. This system is based on the immobilization of cells using encapsulating gels, 
such as alginate, which protect cells against mechanical damages. Immobilization also 
facilitates the re-use of cells in continuous or semi-continuous culture, allowing higher 
inoculums than standard methodologies (James, 2001).  
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Differentiated organs such as hairy roots and shooty teratomas have also been developed 
for protein production. Hairy root cultures have been used for decades to produce 
secondary metabolites such as resveratrol (Medina-Bolivar et al., 2007). To generate hairy 
roots, wounded transgenic host plant is co-cultivated with Agrobacterium rhizogenes which 
transfers rol and aux genes which are responsible of root phenotype and induction 
(Sivakumar, 2006). Hairy root cultures, grown in hormone-free medium, are genetically 
stable over time and allow uniform expression of proteins at high level in relatively short 
periods of time (Franconi et al., 2010). Secretion of proteins is also allowed in root cultures 
which can be cultured in bioreactors or in hydroponic tanks from where they take water and 
nutrients while releasing proteins continuously (Knäblein, 2005). Shooty teratomas are 
generated from transgenic seedlings co-cultured with A. tumefaciens strain T37. After co-
culture and Agrobacteria elimination, shoots are cultured in liquid medium (Sharp & Doran, 
2001).  
2.2 Emerging plant-based systems 
In the last decade alternative novel expression systems have been developed for the 
production of biopharmaceuticals. We would like to highlight the potential of novel systems 
such as mosses, algae and aquatic plants which can be cultured in contained conditions in 
bioreactors. 
Mosses as multicellular eukaryotic organisms can produce biologically active therapeutic 
proteins. Physcomitrella patens is the model organism which has been studied for a long time. 
It can be cultured during its complete lifecycle, but when cultured in liquid medium 
vegetative growth is favored (Franconi et al., 2010). The fact that P. patens is grown in small 
plant fragments, and not as protoplast, provides genetic stability avoiding somaclonal 
variation (Knäblein, 2005). The moss is photoautotrophic and only requires inorganic salts, 
water and CO2 for growth, so it is easily cultured in stirred glass tanks or tubular 
photobioreactors. The most interesting feature of P. patens is its high frequency of 
homologous recombination which facilitates the precise knockout of genes (Decker & Reski, 
2007). In this context, genes for ┙(1,3)-fucosyltransferase and ┚(1,2)-xylosyltransferase were 
disrupted by homologous recombination to obtain double knockout clones of P. patens with 
no allergenic N-glycans (Koprivova et al., 2004). The potential of this species for 
biopharmaceutical production gave rise to the company Greenovation in 1999. Since 2001, 
the company is developing the “bryotechnology”, using double-knockout strain of P. patens 
cultured in photobioreactors. Currently this company is producing a variety of 
biopharmaceuticals such as growth factor (VEGF), serum proteins (HSA), peptide hormones 
(EPO), enzymes (phosphatase), vaccines and a wide range of oncology mAb´s in 100L 
tubular bioreactors and 200L disposable bag systems (www.greenovation.com). 
Microalgae represent a diverse group of prokaryotic (cyanobacteria) and eukaryotic 
photosynthetic microorganisms that are found in marine and freshwater environments. 
Microalgae combine simple and inexpensive growth requirements and ability for post-
transcriptional processing of proteins, with the rapid growth rate and potential for high-
density culture (Walker et al., 2005). Most green algae are classified as generally regarded as 
safe (GRAS), making processing of expressed products more amenable to regulatory issues 
(Potvin & Zhang, 2010), and offering a safe platform for vaccine production. Microalgae can 
be grown in contained bioreactors in a matter of weeks from initial transformation event to 
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large-scale protein production, and as single cell type culture, there should be less variation 
in protein accumulation, making downstream processing more uniform (Specht et al., 2010). 
However, light utilization and distribution in the bioreactor represents a limiting factor for 
cell growth which requires careful design of bioreactors. In this regard, heterotrophic 
growth using glucose as carbon source should be advantageous for well established “dark” 
bioreactors allowing high cell density (Franconi et al., 2010). Chlamydomonas reinhardtii is the 
most successfully used microalgae, because it is genetically well characterized with all three 
genomes (the nuclear, chloroplast and mitochondrial) sequenced, and genetic trans-
formation methods are well established (Rasala & Mayfield, 2011). Proteins such as human 
antibodies (Mayfield & Franlikn, 2005), human glutamic acid decarboxylase 65 (hGAD65) 
(Wang et al., 2008), domain 14 of fibronectin (14FN3), VEGF and HMGB1 (Rasala & 
Mayfield, 2011) have been produced in C. reinhardtii.  
Finally we would like to pay attention to aquatic higher plants from Lemnaceae family such 
as those from Lemna, Spirodela and Wolffia genus. These edible plants are safe, fast-growing, 
and easy to grow and harvest species amenable to genetic transformation using A. 
tumefaciens or biolistic method (Weathers et al., 2010). Lemna minor has been used to produce 
mAb´s fused with an RNA interference construct targeting the expression of endogenous 
genes ┙(1,3)-fucosyltransferase and ┚(1,2)-xylosyltransferase to obtain an antibody without 
plant specific N-glycans (Cox et al., 2006). Many therapeutic proteins have been expressed in 
this system, mainly by Biolex Company and its subsidiary LemnaGene who produce 
interferon for hepatitis C treatment, plasmin for thrombosis treatment and anti-CD20 
antibody optimized for the treatment of non-Hodgkin’s B-cell lymphoma 
(www.biolex.com). At the present time, Spirodela oligorrhiza, with an expression level for 
GFP protein of 25% of TSP represents the best expressing system for nuclear transformation 
in higher plants (Franconi et al., 2010).  
2.3 Factors influencing therapeutic protein production in plants  
Many authors agree that one of the most important limitations of transgenic plants is their 
low expression level of recombinant proteins. Increasing the amount of recombinant protein 
is crucial for the system to be economically viable. The yield of recombinant proteins 
produced in plants depends on many factors: the intrinsic limitations of host plant, 
limitations imposed by transgene expression and protein stability, which are optimized by 
careful design of expression vector, and downstream processing. Finally, we would like to 
analyze the environmental factors affecting transgenic plants in open field. 
2.3.1 Choice of host plant 
The range of plant species amenable to genetic transformation is very wide so there is no an 
ideal host for molecular farming. There are many factors needed to be taken into account 
when choosing the host plant: from production factors such as infrastructure availability, 
storage and distribution cost, or plant productivity, to factors affecting environment and 
human health and food safety (Schillberg & Twyman, 2007).  
Usually host plants are divided into food crops and non-food crops. Tobacco is the most 
used specie among non-food crops due to its easy of genetic transformation (both nuclear 
and chloroplast genomes), high biomass yield and seed production, and ability to produce 
many therapeutic proteins (antibodies, vaccines, cytokines, serum and blood proteins, 
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hormones). Its widespread use has led to the production of low-alkaloid cultivars suitable 
for oral delivery of vaccines (Tremblay et al., 2010). It has also been reported that the 
expression of biologically active GM-CSF in commercial sugarcane which is propagated 
vegetatively from stem pieces offering a “secure” platform for production of recombinant 
proteins (Wang et al., 2005). Food-crops include seed-crops, vegetables and fruits. Species 
such as cereals, rice, maize, soybean, or barley allow the expression of recombinant proteins 
in the seed which enables the long-term storage and the containment of proteins avoiding 
the exposure of non-target organisms. However seed-crops must go through a flowering 
cycle to produce seeds, so it is very important to control pollen transfer (Sparrow et al., 
2007). Oilseed crops are useful for protein production because the fusion of recombinant 
proteins to the endogenous protein oleosin allow the easy recovery of recombinant proteins 
(Stoger et al., 2005). Vegetable crops include potato, worldwide cultivated specie with a very 
well-developed agricultural infrastructure. Tuber has been used mainly for oral vaccine 
production using tissue-specific promoter patatin. This vegetative organ offers stability to 
the recombinant protein. Carrot, alfalfa, lettuce and spinach have also been used for vaccine 
production because can be consumed raw, because can be grown again after leaf harvest, or 
because are very easy to scale-up (Sparrow et al., 2007). Fruits such as tomato and banana, 
more palatable than potatoes for raw consumption, are suitable for oral vaccines because of 
high biomass yield (tomatoes) and easy distribution (bananas) (Kamenarova et al., 2005).  
2.3.2 Design of the expression vector 
The expression vector is the vehicle to integrate the gene of interest into the plant genome. 
As stated before, the final yield of recombinant protein depends on many factors, and most 
of them can be addressed through inclusion of suitable regulatory sequences in the vector. 
In this context we can control factors that affect transcription, translation as well as protein 
accumulation. Figure 1 shows the schematic representation of a general expression vector 
showing potential regulatory sequences.  
 
Fig. 1. Schematic diagram of plant expression vector showing the main regulatory 
sequences. SAR, scaffold attachment region; UTR, untranslated region; SP, signal peptide; 
KDEL, endoplasmatic retention signal; SKL, peroxisomes target sequence serine-lysine-
leucine; PTP, plastid transit peptide; VSD, vacuole sorting determinant. 
2.3.2.1 Promoter 
This is one of the most important factors affecting transcription of genes because it is 
responsible of when, where and how does the gene transcribe. Promoters can be from plant 
or viral origin and usually are divided into constitutive, tissue-specific and inducible 
categories. Constitutive promoters drive the continuous expression of the transgene in all 
plant tissues. The best known and most used promoter is derived from the cauliflower 
mosaic virus (CaMV35S), a strong promoter mainly used for dicot species (Xu et al., 2011). 
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The duplication of an enhancer region located in the 5’ region of CaMV35S promoter 
allowed the development of the strongest version commonly known as double CaMV35S 
(2xCaMV35S) (Kay et al., 1987). For monocot species, rice actin gene or bean arcelin gene 
promoters are most used. The choice of promoter also depends on the nature of recombinant 
protein: when the protein of interest is toxic for the host plant, tissue-specific expression 
could be a helpful strategy (Desai et al., 2010). This type of promoter allows the control and 
restricted expression of transgenes to specific tissues such as leaf (small subunit of Rubisco), 
seeds (maize globulin-1, barley D-hordein, rice glutelin), and storage organs (tuber patatin). 
Inducible promoters allow not only the tight control of gene expression, but also the 
quantity of expression level. Induction can be regulated through chemical stimuli (steroid, 
sucrose, salt) and/or environmental factors (light, temperature, wounding). In this kind of 
promoters it is very important to specify between promoter and inductor, the rapid 
response upon induction, and the safety of the inducer for plant (Corrado & Karali, 2009).  
2.3.2.2 5’ UTR sequences 
The UTR sequences are located in the upstream region of ORF and are related to the 
efficiency of initiation of translation. In eukaryotes this process is thought to follow the 
scanning mechanism conducted by small subunit of ribosome from 5’cap of mRNA through 
the untranslated leader until the first start codon (AUG) is found (Kermode, 2006). Including 
5’ UTR sequences from Alfalfa mosaic virus (AMV), Tobacco mosaic virus (TMV), Chalcone 
synthase (CHS), or Alcohol dehydrogenase (NtADH) have been successfully used to enhance 
the translation efficiency, allowing transgene levels 30 to 100-fold higher (Satoh et al., 2004; 
Schiermeyer et al., 2005). 
2.3.2.3 Terminator sequences 
Also known as polyadenylation signals, these sequences are very important for RNA 
stabilization because they are responsible for the correct processing of RNA after stop codon 
(Desai et al., 2010). The most commonly used terminator sequences are derived from the A. 
tumefaciens nopaline synthase gene which has been used successfully in both dicot and 
monocot plants.  
2.3.2.4 Codon optimization of transgenes 
Many of the transgenes introduced in plants for biopharmaceutical production come from 
humans. Codon usage between divergent species is often very different and will affect the 
expression level of recombinant proteins (Lessard et al., 2002). Based on available data of 
codon usage for a given host plant, transgene codons with the lowest usage frequency are 
modified by changing the nucleotide sequence without changing the amino acid sequence 
(Desai et al., 2010).  
2.3.2.5 SAR/MAR sequences 
The inclusion of sequences containing scaffold/matrix attachment regions (SAR/MAR) 
flanking the expression cassette has been used as a mechanism to increase transgene 
expression. SAR/MAR are AT-rich DNA sequences of 300-500 bp-long which interact with 
nuclear scaffolds organizing the structure of the genome (Allen et al., 2000). These sequences 
facilitate transcription of genes by changing the chromatin topology into less condensed 
regions (Kermode, 2006). With the use of SAR/MAR sequences it is possible to increase 
transgene expression levels through stabilization of the expression in progeny and reduction 
of expression variability (Ulker et al., 1999).  
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2.3.2.6 Subcellular targeting 
Specific targeting of recombinant proteins to plant organelles not only guarantees the correct 
post-translational modifications required, but also allows the enhancement of protein 
stabilization, minimizing proteolytic degradation and facilitating downstream processing 
such as purification (Kermode, 2006). Eukaryotic preproteins synthesized with an N-
terminal signal peptide are targeted to the secretory pathway. In the absence of signal 
peptide, recombinant protein is accumulated into the cytosol. In most cases this is not an 
appropriate compartment for recombinant proteins due to its hydrolytic activity and its 
negative redox potential which is unfavorable for protein folding (Benchabane et al., 2008).  
In the case of proteins with signal peptide and no further targeting, expressed proteins are 
secreted from the ER to the apoplast. This compartment has been implicated in the 
production of proteolytic fragments in several transgenic plant systems due to proteases 
found in the secretory pathway between the ER and Golgi (Doran, 2006).  
One of the most used compartments within plant cells for subcellular targeting is the ER. 
This organelle has many advantages for recombinant protein accumulation due to its 
specific characteristics. ER has very low hydrolytic activity and can tolerate unusually high 
accumulation of proteins without compromising plant development and reproduction 
because of its plasticity to become a reservoir of protein and oil bodies (Vitale & Pedrazzini, 
2005). Recombinant proteins targeted to ER are protected from proteolytic degradation and 
correct folding and disulphide bond formation are allowed (Benchabane et al., 2008). 
Inclusion of KDEL/HDEL tetrapeptide in the C-terminal region of the protein ensures ER-
retention. Targeting recombinant proteins into the ER has led to an increase in expression 
levels from 4.5 to 100-fold (Fiedler et al., 1997; Schouten et al., 1996; Torres et al., 1999).  
Another suitable cell compartment for recombinant proteins accumulation is the vacuole. 
Important functions of this organelle include control of cell turgor, turnover of 
macromolecules, sequestration of toxic compounds, and finally, storage of high-energy 
compounds (Benchabane et al., 2008). From two types of vacuoles in plants, only protein 
storage vacuoles which are very abundant in seeds are suitable for recombinant proteins 
because of their mild environment (Stoger et al., 2005).  
With chloroplast transformation, it is possible to target the recombinant protein to this 
organelle through the suitable targeting signals. The chloroplast-transit peptide of potato 
rbcS1 gene allowed the expression of human papillomavirus type 16 L1 (HPV-16 L1) protein 
into chloroplast of Nicotiana benthamiana, obtaining expression levels of up to 11% of TSP 
(Maclean et al., 2007). Moreover, chloroplast targeting can avoid the toxic effect of 
recombinant protein in the cytosol (Gils et al., 2005; Hühns et al., 2008).  
It has also been reported that the subcellular targeting to mitochondria (Menassa et al., 2004) 
and chloroplast and peroxisomes at the same time, it is possible to accumulate the 
recombinant protein 160% of that in chloroplasts alone and 240% of that in peroxisomes 
alone (Hyunjong et al., 2006).  
2.3.2.7 Protein/tag fusions 
Expression of the recombinant protein attached to a protein with enhanced stability may 
prove to be useful to enhance fusion partner. In plants, several authors have reported the 
suitability of engineering fusion proteins to improve expression levels (Wirth et al., 2006; Xu 
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et al., 2010). Many fusion proteins can also serve as purification tags due to their specific 
binding features or easy of recovery, but those will be discussed in the next section. 
2.3.3 Downstream processing 
The downstream processing of recombinant proteins includes protein extraction, 
purification and characterization, a process that may represent 80% or more of total 
production costs (Twyman et al., 2003). Purification strategies may be based on standard 
chromatographic techniques, but affinity purification using His-tag, protein A, or 
glutathione S-transferase (GST) is an alternative approach widely used by researchers 
(Arnau et al., 2006). We have successfully used His-tag to purify human placental lactogen 
(hPL) from tobacco leaf tissue (Urreta et al., 2010). 
Fusion of recombinant proteins to endogenous proteins such as oleosin or ┛-zein is also very 
attractive for therapeutic protein production and is gaining more attention for commercial 
issues. Oleosin fusion platform has been developed by SemBioSys Inc. 
(www.sembiosys.com) and allows recombinant protein to be targeted to the oil bodies in 
rapeseed and safflower. The purification is based on separation of oil bodies by simple and 
inexpensive schemes (Schilberg & Twyman, 2007). Similarly, fusion of recombinant protein 
to ┛-zein, a prolamin of maize, induces protein body formation and high accumulation of 
foreign protein within ER. Protein bodies are insoluble and easily purified by centrifugation 
(Vitale & Pedrazzini, 2005). An alternative emerging purification strategy relies on elastin 
like polypeptide (ELP) fusion to recombinant protein (Floss et al., 2009). 
2.3.5 Environmental factors 
Plants, as grown in the field or in the glasshouse, are subjected to environmental factors. 
Those factors influence their health condition, and subsequently, the quality and the 
quantity of recombinant protein. The stability of foreign protein in plants grown in the field 
is very important because it determines the homogeneity of the product. The most 
important environmental factors are light, temperature, soil (nutrients), water and insect 
attacks (Jamal et al., 2009). Most of these factors can be controlled to greater or lesser extent 
for plants cultivated in the glasshouse. However, when transgenic plants are grown in the 
field, light and temperature became the critical factors. Light is crucial for plants as energy 
source and temperature also affects plant growth and productivity being especially 
dangerous at high temperatures. The analysis of the influence of plant´s physiology on 
recombinant protein accumulation is crucial to plan the best strategy for plant harvesting 
(Conley et al., 2010).  
Although protein production in plants has long been investigated, the most of the reported 
works are based on plants grown in glasshouses under controlled conditions. Arlen et al. 
(2007) reported that the field production of chloroplast derived interferon (IFN) from 
tobacco plants. They cultivated 0.26 acre containing 7369 plants and obtained 107.7 kg of 
biomass from a single harvest. This biomass contained approximately 87 g IFN (0.8 mg g-1). 
It must be noted that tobacco plants can be harvested 4-6 times within a grow season from a 
1 acre. They also tested light and temperature influence on glasshouse grown plants 
revealing the importance of leaf maturity and illumination, and most importantly, they 
observed higher IFN yield in those plants (1-3 mg g-1 fresh weigh).  
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3. Case study: Production of human placental lactogen in transgenic plants 
Human placental lactogen (hPL), or chorionic somatomamotropin, is a 22 kDa peptidic 
hormone secreted by the placenta during pregnancy (Barrera-Saldaña et al. 1982). This 
protein is involved in the adaptation of islets of Langerhans to pregnancy through the 
regulation of beta (┚) cell mass and function (Brelje et al. 1993). The capacity of hPL to 
improve ┚ cell function, proliferation and survival in vitro and in vivo (Vasavada et al. 2000) 
makes possible its use as therapeutic protein for Langerhans islet transplantation to patients 
with type 1 diabetes. The transplantation of pancreatic tissue has become an interesting 
alternative treatment for diabetes, allowing the independence of patients to insulin injection. 
Unfortunately, the low availability of pancreatic tissue and great prevalence of the disease 
limits the potential of this treatment. Therefore, hPL together with other peptidic growth 
factors (HGF and PTHrP) belongs to the short list of proteins capable of improving the 
critical beta cell parameters, namely function, proliferation and survival, to improve tissue 
availability for islet transplantation (Fujinaka et al. 2007). Currently, the commercially 
available hPL protein is purified from human placenta which increases not only the risk of 
human pathogen propagation but also increases the cost of the protein in the market. This 
hormone has also been expressed in E. coli as inclusion bodies, which required the 
solubilization and refolding of the protein (Lan et al., 2006), making the process and the 
product more expensive. Due to the potential of hPL protein for type 1 diabetes treatment, 
we analyzed the suitability of potato plants as an alternative production system for hPL 
protein. In our laboratory, we thought that due to the potential of PL as a candidate for the 
treatment of type-1 diabetes, it would be very interesting to investigate alternative 
production strategies for the safe and easy production of this protein at low cost. Of course, 
plants represent for us the better production platform for all the reasons previously exposed 
and discussed, as well as for our experience on therapeutic protein production in plants. 
We have successfully expressed hPL protein in Nicotiana tabacum cv. Xanthi plants reaching 
expression levels of up to 1% of TSP (Urreta et al., 2010). In vitro bioassays using the rat 
insulinoma (INS-1) cell line showed that recombinant protein was able to induce cell 
proliferation, demonstrating that plant cells can produce the biologically active hPL protein. 
Due to the difficulty to evaluate the relative performance of different crops for commercial 
production of therapeutic proteins which requires the production of the same protein in 
different host plant (Schilberg & Twyman, 2007), we attempted to produce hPL protein in 
Solanum tuberosum. We chose potato because it is easily transformed and widely used for 
molecular farming. Potato is an important crop worldwide and in our region, Álava (Spain). 
Indeed, our research institute has a long experience in the cultivation and improvement of 
this crop, being the reference germplasm bank in Spain.  
To achieve our objective, the cDNA encoding hPL gene was obtained by RT-PCR from 
human placenta mRNA (Clontech) as previously described (Urreta et al., 2010). Briefly, the 
amplified sequence of 654-bp was ligated into pGJ2750 binary vector (kindly provided by 
Max Planck Institute, Köln, Germany) to obtain pNEKhPL1 expression vector where hPL 
gene is regulated by the promoter and terminator of CaMV 35S gene. The expression vector 
was introduced into Agrobacterium tumefaciens EHA105 strain and co-cultivated with 
Solanum tuberosum cv. Désirée leaf disks following the protocol described by Dietze et al. 
(1995). The regenerated shoots (Figure 2A) were subcultured in MS medium (Murashige & 
Skoog 1962) supplemented with kanamycin (100 mg L-1) at 22ºC, under 120 µmol m-2 s-1 of 
photon flux and a 16-h photoperiod in a growth chamber. Most of the regenerated putative 
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transgenic plants had the same phenotype as the non transformed wild type plants (Figure 
2, B-C). Integration of hPL and neomycin phosphotransferase (nptII) genes in the genome of 
regenerated plants was verified by polymerase chain reaction (PCR) using specific primers. 
All transgenic plants screened by PCR were positive (Figure 2, D-E), ensuring the correct 
integration of T-DNA in the genome of plants. Further molecular characterization of 
recombinant hPL protein was assessed by western blot. The proteins were separated on 12% 
polyacrylamide gels under reducing conditions and transferred to a nitrocellulose 
membrane (Bio-Rad, Hercules, CA, USA). The blots were blocked for 1 hour in PBS with 
0.05% (v/v) Tween-20 (PBS-T) and 5% non-fat dry milk, and incubated with polyclonal anti-
hPL antibody (RB9067, NeoMarkers, Fremont, CA, USA). Blots were incubated with Anti-
Rabbit IgG secondary antibody conjugated with alkaline phosphatase (Sigma-Aldrich, St 
Louis, MO, USA). Antibody binding was detected with NBT/BCIP (Sigma). The 
recombinant protein was detected in leaf protein extracts of transgenic plants cultivated in 
the greenhouse, which showed the expected molecular weight of 22 kDa (Figure 2F) 
demonstrating that plant cells are able to process signal peptides from human origin.  
 
Fig. 2. Phenotypic and molecular characterization of transgenic potato plants. A, 
regenerated shoots obtained from leaf tissue co-cultured with A. tumefaciens. B, phenotype of 
potato plants cultivated in the glasshouse. C, tubers from transgenic lines (scale 1:2 cm). D 
and E, PCR amplification of hPL (D) and nptII (E) genes in the genome of regenerated 
plants. 1-12 independent lines; c+, pNEKhPL1 vector; wt, non transformed plant. F, western 
blot of transgenic plants cultivated in the glasshouse. C+, 10 ng of commercial hPL protein 
(NeoMarkers); 1-5, 20 µg of TSP from different transgenic lines. 
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The amount of hPL protein was determined by sandwich enzyme linked immunosorbent 
assay (ELISA) in leaf tissue of plants grown in vitro and cultivated in the greenhouse. 
Maxisorp 96-well microtiter plates were coated with polyclonal anti-hPL antibody 
(NeoMarkers) overnight at 4ºC. The wells were blocked with 1.5% horse serum in PBS-T and 
then samples as well as serial dilutions of commercially available hPL protein were added in 
PBS for 1 hour at 37ºC. Monoclonal anti-HPL antibody (MCA322, Serotec, Oxford, UK) and 
alkaline-phosphatase conjugated goat anti-mouse IgG antibody (Sigma) were coated 
subsequently to finally detect color development using 4-nitrophenyl phosphate (Sigma-
Aldrich). Absorbance was measured at 405 nm in a microplate reader (Multiskan RC, 
Labsystems, Helsinki, Finland) and TSP content was determined by the Bio-Rad protein 
assay. The results showed that plants cultivated in the greenhouse had 2.4-fold higher 
expression levels than those grown in vitro (Table 1). The lower protein levels detected in 
plants grown in vitro could be due to the stressful conditions of culture conditions. It has 
been described that the artificial medium and the high air humidity and low gas exchange of 
this culture type could induce disturbances in plant development (Kadlecêk et al. 2001) 
which possibly limit the production of endogenous and foreign protein levels. Using the 
expression vector pNEKhPL1, the expression levels reached a maximum of 0.21% of TSP. 
These expression values are similar to those reported by other authors using vectors similar 























Table 1. Yield of the recombinant human placental lactogen protein expressed in potato 
plants grown under different conditions and in different organ/tissues. The expression 
levels were measured by enzyme-linked immunosorbent assay (ELISA) and are represented 
as recombinant protein per total soluble protein content (ng hPL µg-1 PTS).  
Compared to the levels obtained in tobacco plants (Urreta et al. 2010), those reached in potato 
plants are much lower. However it must be taken into account that pNEKhPL1 expression 
vector is the simplest version of a plant expression vector; with no ER-retention signal, SAR 
sequence, nor enhanced 35S promoter included in pNEKhPL2 vector used in tobacco plants 
(Urreta et al., 2010). This difference in expression levels highlights the importance of the design 
of expression vector including regulatory sequences suitable to achieve our goals.  
Regarding to the influence of host plant, in our laboratory we also transformed tobacco 
plants with pNEKhPL1 expression vector, obtaining a maximum expression level 2-fold 
higher than that obtained in potato (data not shown). So in the case of hPL production in 
plants, tobacco seems to be more suitable than potato with allowing higher expression levels 
in leaf tissue of plants cultivated in the greenhouse.  
Because of the constitutive nature of CaMV35S promoter, we also analysed the expression 
level of recombinant hPL in tubers from 16 transgenic plants. We obtained elevated levels of 
recombinant protein in this tissue, with a mean value 2-fold higher than that of leaf tissue 
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(Table 1). The maximum hPL expression level was 0.18% of TSP, slightly lower than the 
maximum in leaf tissue. These results are in the range of expression levels reported by other 
Authors in potato tubers using CaMV35S promoter (Mason et al., 1998; Zhou et al., 2003; 
Bielmet et al., 2003). Although CaMV35S promoter is not tuber specific, the expression levels 
obtained are also similar to those reported by Mason et al. (1996) and Castañón et al. (2002) 
using tuber specific promoters such as patatin. It is also noteworthy that from the tubers 
tested, 4 of them did not show detectable levels of hPL.  
In order to assess the suitability of hPL production in plant cell cultures we induced the 
formation of callus from leaf tissue of transgenic plants cultivated in vitro (Figure 3, A). Leaf 
explants were cultured in MS medium supplemented with casein hydrolysate (0.2% w/v), 
2,4-D (5 mg L-1) and kinetin (0.2 mg L-1), and incubated at 23ºC in the dark. Friable callus 
developed in 3-4 weeks (Figure 3, B) which were analysed by western blot. Recombinant 
protein was detected at 22 kDa, as expected, but not in all lines tested (Figure 3, C). 
Fig. 3. Induction and characterization of callus tissue. A, induction of callus from leaf tissue 
cultured in MS medium supplemented with 2,4-D and kinetin. B, isolated callus line from 
leaf tissue and subcultured to fresh medium. C, western blot of callus protein extracts (10 
µg). c+, commercial hPL protein (30 ng) (NeoMarkers); 1-7, transgenic lines; wt, callus 
induced from leaf explants of non transformed potato plants. 
Although those calli were kanamycin-resistant, they did not express hPL protein. This could 
be as a result of promoter methylation during callus induction process as observed by other 
Authors (De Carvalho et al., 1992; Fojtova et al., 2003). The hPL protein levels were 
measured by ELISA. Results showed that a mean value 7-fold higher than that of leaf tissue 
of plants grown in the glasshouse, reaching a maximum level of 0.74% of TSP (Table 1). The 
expression of hPL protein in callus is favored because of the lower TSP content in this tissue. 
Data presented in this work represents a good starting point to further analyze the 
suitability of cell suspensions as an alternative plant-based expression system for hPL 
protein production. As previously discussed, plant cell cultures offer many advantages over 
whole plants for the production of human therapeutics, like rapid growth and easier 
purification strategies when the protein is secreted to the culture media. The expression 
vector pNEKhPL1 allows the targeting of hPL to the apoplast and hence to the culture 
medium. Moreover, using bioreactors we can avoid the release of genetically modified 
organisms to the field, and improve protein yields through the control of growth parameters 
allowing a homogeneous batch to batch production. 
Finally, to further characterize the transgenic potato plants expressing the hPL protein, we 
analyzed the stability of the recombinant protein in the second generation (vegetative) of 
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four transgenic lines. Recombinant hPL levels were measured by ELISA, showing that one 
of the lines lost the expression of hPL and in the remaining lines the levels ranged from 0.2 
to 0.38 ng µg-1 of TSP. These levels are higher than those of their counterpart grown in vitro, 
and similar to that of first generation cultivated in the glasshouse.  
All the results obtained in this work suggest that although hPL protein is correctly produced 
in potato leaf tissue, tubers accumulate higher mean protein levels, allowing the storage of 
the protein. Further investigation will be necessary to analyze the stability of the protein in 
long term storage and the influence of temperature conditions needed to maintain its 
integrity. Although potato plants show lower expression levels than tobacco plants 
transformed with the same expression vector, expression levels in callus tissue opens the 
possibility for the production of hPL protein using plant cell cultures.  
4. Conclusion 
Transgenic plants represent an attractive production platform for therapeutic proteins due 
to all of the previously mentioned features. However, the commercial production of plant-
made proteins is still limited, as compared to other expression systems currently available. 
Twenty two years after the first antibody produced in plants, the great research efforts of 
public and private institutions have lead to hundreds of plant-made protein publications 
and patents. Plant-based systems have demonstrated their suitability for protein production, 
ensuring their capacity for correct production of many types of therapeutic proteins and 
their great versatility to allow the production of proteins in different conditions. Many 
companies are exploiting plant systems for protein production (SemBiosys, Protalix, Dow 
Agrosicences, Méristem Therapeutics) but the pharmaceutical industry still shows 
reluctance to integrate plant systems in their production strategy. The lower protein levels 
obtained in plant systems can be greatly improved through the careful design of expression 
vectors and the choice of host plant. On the other hand, there is no biosafety and/or 
regulatory issue that can´t be solved. We hope that all the efforts made until now in the 
research field will be rewarded with a greater number of therapeutic proteins produced in 
plants in the market, for the benefit of society.  
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